Fucaso® Celebrates First Anniversary: A Milestone in Treating Relapsed/Refractory Multiple Myeloma

On August 2, all employees of IASO Bio celebrated together in multiple locations, including Nanjing, Shanghai, and California, USA.The CAR-T product for treating relapsed and refractory multiple myeloma (RRMM) — Foksoo^®(IASO Bio's Ixcellen Injection) Celebrates One-Year Anniversary Since Market LaunchLooking back on the past year, we have brought new hope of treatment to numerous patients, which has greatly encouraged us. Looking ahead to the future, in order to enable more patients around the world to receive effective treatments in a timely manner, IASO Biotherapeutics understands the heavy responsibility and will continue to move forward with even greater perseverance.

"Reindeer can survive in harsh environments and help humans carry goods because they are united and unafraid of challenges." At the celebration, Ms. Zhang Jinhua, founder, chairperson, and CEO of IASO Bio, first thanked all employees for their united efforts and perseverance in overcoming numerous challenges together.It took only 3 years and 9 months to complete the process from Fokasol.^®The feat of IASO Bio's IND (Investigational New Drug) approval to market approval. This achievement has significantly narrowed the time gap for Chinese myeloma patients to access this innovative therapy compared to patients in the United States.

Since its launch in China, Fokosu^®The efficacy and safety have been widely recognized by clinical experts. According to Mr. Hua Zhang, Chief Commercial Officer of IASO Bio, Fucosine^®Has benefited hundreds of patients. Meanwhile, to improve the accessibility of this therapy, the company is actively exploring diversified and innovative payment models.

As the first CAR-T product independently developed and fully manufactured in China for the treatment of relapsed or refractory multiple myeloma, Fokasium^®Represents a truly "Made-in-China" innovative drug.Ms. Jin Hua Zhang stated that in order to ensure patients from different regions across the globe can benefit from this highly effective innovative drug, IASO Bio is actively promoting Fokasol.^®The Internationalization Process。Currently, patients from over 10 countries and regions have come to China for treatment. Meanwhile, under the "going global" strategy, IASO Bio is actively seeking overseas technology transfer and exploring Fokasol.^®Overseas Registration Declaration.

In China, Focasus^®On the first anniversary of its listing, we received congratulatory messages from several clinical experts. They not only expressed recognition of the clinical value of this innovative therapy but also placed high hopes on IASO Bio's future R&D efforts—hoping that this therapy will benefit earlier-stage patients.

This is also the goal that IASO Bio has always pursued. We are not only innovating to increase production capacity, but also continuously advancing the development of Equecabtagene Autoleucel (Forblood).^®) Clinical research on the treatment of multiple myeloma. Dr. Jie Chen, Chief Medical Officer of IASO Bio, revealed,The Phase III clinical trial (FUMANBA 3) for the 2-3 line treatment of multiple myeloma is proceeding smoothly as planned, while its real-world study and long-term follow-up research have also been initiated.。

In the future, IASO Bio will continueBased in China, with a global perspective, let "China-made" Fokasartib^®And more advanced cell and gene therapies are bringing "hope" to more patients worldwide, offering them the possibility of a cure.。